The EkoSonic^® Endovascular System now with MACH4e

EKOS set the standard for safety and completeness in dissolving clots with its first generation of MicroSonic™ technology.

It raised the bar with MACH4. And now, EKOS scientists have refined the performance yet again with MACH4e; up to 40% faster¹ than MACH4.

With no evidence of thrombus breakage². And no hemolysis³. Less time to complete dissolution means a lower lytic drug dosage.
And that means an even lower risk of complications.

A preferred alternative to current therapies

• Penetrates thrombus, in difficult–to-reach places, such as behind valves⁴
• Uses 50 - 70% less lytic drug⁴
• No thrombus fracture or breakage², reducing the risk of distal embolism
• Exposes thrombus to greater drug uptake⁵
• Captures drug within thrombus⁵
• No damage to valves³ or the vascular wall
• No hemolysis³. Does not fracture red blood cells, so there is no adenosine release and no additional compromise to renal function
• Higher level of vessel patency, Removes the thrombus more completely, possibly reducing the risk of Post-Thrombotic Syndrome (PTS)
• Shortest physician lab time

Intended Use

The EkoSonic Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Contraindications* Not designed for peripheral vasculature dilation purposes.* This system is contraindicated when, in the medical judgment of the physician, such procedure may compromise the patient’s condition.

« Back »

Peripheral Vasculature: Both the EkoSonic Endovascular System and the EkoSonic SV Endovascular Systems are intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, in the peripheral vasculature.

Pulmonary Artery: The EkoSonic Endovascular System is intended for the controlled and selective infusion of physician – specified fluids including thrombolytics, into the peripheral vasculature. The EkoSonic Endovascular System is also intended for the infusion of solutions into the Pulmonary Arteries.

« Back »

1. EKOS in vitro data on file
2. Braaten, J., Goss, R., Francis, C. “Ultrasound Reversibly Disaggregates Fibrin Fibers.” Thromb Haemost 78 (1997) 1063-8.4.
3. Soltani, A., et al “Absence of biological damage from prolonged exposure to intravascular ultrasound.” Ultrasonics 46 (2007) 60-67
4. Parikh, S., et al. Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience. Journal of Vascular and
   Interventional Radiology, April, 2008, 19:4, pp521-528.1
5. Francis, CW. et al. “Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots.” Ultrasound in Medicine and Biology, 21.3 (1995): 419-424
6. Soltani A, Volz KR, Hansmann DR. “Effect of modulated ultrasound parameters on ultrasound-induces thrombolysis”. Phys Med Biol. 2008. Phys Med Biol, 2008

« Back »